Dynavax enters supply agreement with West for HEPLISAV-B stoppers; CFO also named principal accounting officer

DYNAVAX TECHNOLOGIES CORP

Entered 4-year supply agreement with West Pharmaceutical Services for syringe stoppers for HEPLISAV-B, replacing 2016 agreement.
Obligated to purchase certain volumes; pricing based on annual volume and subject to price index adjustments.
Kelly MacDonald, current CFO, appointed as principal accounting officer effective February 13, 2025.

item 1.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kelly MacDonald

Principal Accounting Officer

DYNAVAX TECHNOLOGIES CORP

Effective: 2025-02-13
Filed: February 14, 2025, 6:59 PM ET

O n February 13, 2025, the Board of Directors of the Company appointed Kelly MacDonald, the Company’s Chief Financial Officer and principal financial officer, as the Company’s principal accounting officer, effective immediately .

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kelly MacDonald was appointed as Principal Accounting Officer at DYNAVAX TECHNOLOGIES CORP.

Action: appointed
Role: Principal Accounting Officer

Exact text from the filing

O n February 13, 2025, the Board of Directors of the Company appointed Kelly MacDonald, the Company’s Chief Financial Officer and principal financial officer, as the Company’s principal accounting officer, effective immediately .

View on SEC.gov

Source: SEC EDGAR

accession 0001029142-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.